New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera
PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, announced today the publication of new results from a Phase 2 clinical study with ropeginterferon alfa-2b, marketed as BESREMi®, for the treatment of patients with polycythemia vera (PV). The study, conducted in China, demonstrated the efficacy and tolerability of ropeginterferon alfa-2b using an alternate dosing regimen that has a higher starting dose and a more rapid dose titration compared to current U.S. label dosing.
The publication, titled “A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera,” was published in Experimental Hematology & Oncology. It was co-authored by researchers